Psychedelic Chemist & `Godfather of Ecstasy' Alexander Shulgin Dies at 88

Alexander Shulgin, chemist and renowned psychonaut who acquainted the world with the drug MDMA - or Ecstasy - died Monday evening at his home in Lafayette, Calif.

Join Our Community of Science Lovers!

This article was published in Scientific American’s former blog network and reflects the views of the author, not necessarily those of Scientific American


Alexander Shulgin, chemist and renowned psychonaut who acquainted the world with the drug MDMA – or Ecstasy – died Monday evening at his home in Lafayette, Calif. after a battle with liver cancer. Shulgin spent much of his life synthesizing and experimenting with hundreds of psychedelic drugs, which he believed would give people a better understanding of the human mind.

Shulgin’s experiences with psychedelics began early, well before they became sacraments for the counter-culture. When he attended the University of California, Berkeley, in the 1950s, he ingested his first consciousness-altering drug, mescaline. He later became a biochemist for Dow Chemical Co., where he concocted new psychoactive compounds and also developed the world’s first biodegradable pesticide.

While working at Dow in 1965, he came across a compound called MDMA (3,4-methylenedioxy-N-methylamphetamine), patented by the pharmaceutical company Merck in 1912 and then largely ignored for decades. Shulgin devised a simple method to make the compound and gave the drug to his psychotherapist friend, Leo Zeff, who then distributed it to thousands of other therapists for use in talk therapy sessions. Before long, the drug entered mainstream culture and received its popular name, Ecstasy. Though the Drug Enforcement Administration banned MDMA in 1985, about 8 million people in U.S. had tried it by 2001. Today, it’s the drug of choice in clubs all over the world.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Shulgin spent a good part of his life formulating psychoactive drugs in the lab he built behind his home, substances that he tested out on himself, his wife, and friends. Shulgin estimated that he had tried over 200 psychedelics, many of them his own creations. “I take them myself because I am interested in their activity in the human mind. How would you test that in a rat or mouse?" the chemist told Scientific American in a previous interview.

Shulgin thought that some psychoactive drugs, like MDMA, might also have a therapeutic use. He made contributions to the field of psychopharmacology over his lifetime, but lamented the federal government’s increasingly severe restrictions on psychedelics. He recently told Scientific American, "I was very sad to see MDMA achieve the status of a Schedule 1 drug," which the government classifies as a drug with no accepted medical use and bans its production and use. "I felt that it would inhibit research into its medical value and that's the way it's turned out."

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe